Education
About Us
Working with TipRanks
Follow Us
Strata Critical Medical (SRTA)
NASDAQ:SRTA
Top Page
Strata Critical Medical
(NASDAQ:SRTA)
Select Model
Select Model
Rating:50Neutral
Price Target:
$4.50
▼(-10.71% Downside)
The overall stock score is primarily influenced by strong earnings call guidance and revenue growth, despite financial performance challenges and bearish technical indicators. The negative valuation metrics further weigh down the score.
Strata Critical Medical (SRTA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$418.88M
Dividend YieldN/A
Average Volume (3M)714.40K
Price to Earnings (P/E)―
Beta (1Y)2.05
Revenue Growth-5.40%
EPS Growth63.20%
CountryUS
Employees310
SectorIndustrials
Sector Strength72
IndustryAirlines, Airports & Air Services
Share Statistics
EPS (TTM)-0.12
Shares Outstanding86,366,520
10 Day Avg. Volume815,866
30 Day Avg. Volume714,402
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)1.48
Price to Sales (P/S)1.32
P/FCF Ratio-9.27
Enterprise Value/Market Cap0.82
Enterprise Value/Revenue1.35
Enterprise Value/Gross Profit5.54
Enterprise Value/Ebitda-18.97
Forecast
1Y Price Target
$9.25Price Target Upside83.53% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Strata Critical Medical Business Overview & Revenue Model
Company DescriptionStrata Critical Medical (SRTA) is a healthcare technology company focused on developing advanced medical devices and solutions aimed at improving patient outcomes in critical care environments. The company operates primarily in the medical device sector, with a particular emphasis on innovative monitoring systems, diagnostic tools, and therapeutic equipment designed for use in hospitals and emergency medical services. SRTA's core products include state-of-the-art vital sign monitors, portable diagnostic devices, and software solutions that enhance clinical decision-making processes.
How the Company Makes MoneyStrata Critical Medical generates revenue through multiple streams, primarily focusing on the sales of its medical devices and related software solutions to hospitals, healthcare providers, and emergency medical services. The company employs a direct sales force and leverages distribution partnerships to reach a broader market. Additionally, SRTA earns income through service contracts for maintenance and support of its devices, as well as from training programs for healthcare professionals on the effective use of its products. Strategic partnerships with healthcare institutions and research organizations also contribute to revenue through collaborative projects and grants aimed at advancing medical technology.
Strata Critical Medical Earnings Call Summary
Earnings Call Date:Nov 10, 2025
(Q3-2025)
| % Change Since: |
Next Earnings Date:Mar 17, 2026
Earnings Call Sentiment Positive
The earnings call highlighted significant revenue growth, successful strategic transactions, and strong profit margins, setting a positive outlook for future cash flow generation. However, challenges such as the impact of the Joby transaction stock price and ongoing legal issues were noted.Q3-2025 Updates
Positive Updates
Revenue Growth and Profitability
Year-over-year revenue growth accelerated to 29% excluding Keystone, with record segment adjusted EBITDA performance seeing 80% growth. Medical segment adjusted EBITDA margin increased to over 15% in Q3 2025, up from 10.8% in the prior year.
Strategic Transactions and Rebranding
Completed two transformational transactions: divestiture of the passenger business and acquisition of Keystone Perfusion. Rebranded as Strata Critical Medical with a new ticker symbol, SRTA.
Positive Free Cash Flow
Generated positive free cash flow from continuing operations, with expectations to consistently generate free cash flow moving forward.
Strong Performance in New and Existing Services
Revenue from organ placement services more than doubled year-over-year, and a new organ logistics customer was added late in Q3.
Negative Updates
Joby Transaction Stock Price Impact
The $10 million difference in cash proceeds from the Joby transaction was due to a significant decline in Joby's stock price during the measurement period.
Legal Provision for Ongoing Litigation
Booked a legal provision related to ongoing litigation from the go-public transaction, as disclosed in SEC filings.
Company Guidance
During the Strata Critical Medical fiscal third-quarter 2025 earnings call, the company provided robust guidance, highlighting a significant year-over-year revenue growth of 29%, excluding the recent Keystone acquisition. The company reported an all-time high in segment adjusted EBITDA performance, with an 80% increase year-over-year, also excluding Keystone. The medical segment adjusted EBITDA margin improved to over 15% in Q3 2025, compared to 10.8% in the previous year and 12.5% in the first half of the year. Despite a seasonal sequential decline in industry-wide transplant volumes by approximately 6%, Strata's revenue rose 3% sequentially. The company also raised its 2025 revenue guidance to $185-$195 million and reaffirmed its adjusted EBITDA guidance range of $13-$14 million. Additionally, Strata expects medical segment adjusted EBITDA margins to increase in Q4 2025 driven by the Keystone acquisition.Strata Critical Medical Financial Statement Overview
Summary
Blade Air Mobility exhibits strong revenue growth but struggles with profitability, as indicated by negative net profit margins and cash flow challenges. The balance sheet is stable with low leverage, but negative cash flows highlight the need for improved operational efficiency.Income Statement
Blade Air Mobility has shown a positive revenue growth trend with a TTM growth rate of 13.6%. However, the company is struggling with profitability, as indicated by negative net profit and EBIT margins. The gross profit margin has improved slightly over the years, but the company remains unprofitable with a net profit margin of -7.46% in the TTM.45
Neutral
Balance Sheet
The company maintains a low debt-to-equity ratio of 0.0396, indicating low leverage and financial risk. However, the return on equity is negative, reflecting ongoing losses. The equity ratio remains stable, suggesting a solid capital structure despite profitability challenges.55
Neutral
Cash Flow
Blade Air Mobility's cash flow situation is concerning, with negative free cash flow and a declining free cash flow growth rate. The operating cash flow to net income ratio is low, indicating limited cash generation relative to net losses. The company needs to improve its cash flow management to support operations.40
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 254.34M | 248.69M | 225.18M | 146.12M | 23.43M | 31.20M |
| Gross Profit | 62.14M | 58.92M | 42.12M | 22.27M | 2.33M | 4.70M |
| EBITDA | -18.16M | -27.96M | -61.01M | -69.87M | -9.83M | -11.07M |
| Net Income | -18.98M | -27.31M | -56.08M | -27.26M | -10.16M | -10.84M |
Balance Sheet | ||||||
| Total Assets | 257.92M | 256.68M | 294.94M | 325.02M | 17.71M | 277.69M |
| Cash, Cash Equivalents and Short-Term Investments | 113.42M | 127.14M | 166.14M | 194.04M | 12.16M | 277.57M |
| Total Debt | 8.84M | 9.32M | 24.52M | 18.33M | 1.89M | 462.73K |
| Total Liabilities | 34.82M | 34.74M | 60.64M | 50.54M | 6.63M | 272.69M |
| Stockholders Equity | 223.10M | 221.94M | 234.30M | 274.49M | 11.08M | 5.00M |
Cash Flow | ||||||
| Free Cash Flow | -19.55M | -35.51M | -34.46M | -37.86M | -11.20M | -11.16M |
| Operating Cash Flow | 1.29M | -2.52M | -32.35M | -37.13M | -10.82M | -10.30M |
| Investing Cash Flow | 40.42M | -1.02M | 17.09M | 79.34M | -377.00K | -1.05M |
| Financing Cash Flow | -9.99M | -5.76M | -76.00K | -1.08M | 1.18M | 116.00K |
Strata Critical Medical Technical Analysis
Positive
5.04
Price Trends
4.93
Positive
4.56
Positive
3.92
Positive
Market Momentum
-0.06
Positive
52.79
Neutral
51.36
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SRTA, the sentiment is Positive. The current price of 5.04 is above the 20-day moving average (MA) of 4.95, above the 50-day MA of 4.93, and above the 200-day MA of 3.92, indicating a bullish trend. The MACD of -0.06 indicates Positive momentum. The RSI at 52.79 is Neutral, neither overbought nor oversold. The STOCH value of 51.36 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SRTA.
Strata Critical Medical Risk Analysis
Strata Critical Medical disclosed 64 risk factors in its most recent earnings report. Strata Critical Medical reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 1 New Risks
Strata Critical Medical Peers Comparison
UnderperformOutperform
Sector (63)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | $648.92M | 11.68 | 9.99% | ― | 4.27% | 28.47% | |
63 Neutral | $10.79B | 15.43 | 7.44% | 2.01% | 2.89% | -14.66% | |
57 Neutral | $289.69M | 47.37 | 1.35% | ― | -1.64% | 1966.67% | |
50 Neutral | $418.88M | ― | -10.33% | ― | -5.40% | 63.20% | |
47 Neutral | $55.26M | -0.31 | -378.73% | ― | -14.62% | -86.07% | |
45 Neutral | $254.81M | ― | ― | ― | ― | ― | |
42 Neutral | $134.47M | ― | ― | ― | -3.95% | 85.63% |
* Industrials Sector Average
SRTA
Strata Critical Medical
5.04
1.38
37.70%
MESA
Mesa Air Group
1.69
0.81
92.05%
ASLE
AerSale Corporation
6.12
0.34
5.88%
SNCY
Sun Country Airlines Holdings
12.26
-3.05
-19.92%
FLYX
flyExclusive
3.37
1.14
51.12%
SRFM
Surf Air Mobility, Inc.
3.04
1.21
66.12%
Strata Critical Medical Corporate Events
Business Operations and StrategyM&A Transactions
Strata Critical Medical Completes Keystone Acquisition
Positive
Sep 16, 2025
On September 16, 2025, Strata Critical Medical completed the acquisition of Keystone Perfusion Services, a leading provider of organ recovery and normothermic regional perfusion services. This acquisition, valued at approximately $124 million, aims to create an integrated organ recovery platform and diversify Strata’s medical services. The deal is expected to enhance Strata’s market positioning by offering comprehensive transplant services and expanding into non-transplant medical sectors, potentially driving significant revenue growth and operational efficiencies.
The most recent analyst rating on (SRTA) stock is a Buy with a $6.50 price target. To see the full list of analyst forecasts on Strata Critical Medical stock, see the SRTA Stock Forecast page.
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.